3. CorMedix Inc. (NASDAQ:CRMD)
CorMedix Inc. (NASDAQ: CRMD) reaches the top three after developing into a profitable commercial healthcare business led by DefenCath, a catheter-lock solution used to reduce catheter-related bloodstream infections in certain adult hemodialysis patients. Preventing these infections can improve patient outcomes while reducing hospitalizations and healthcare expenses, giving DefenCath both clinical and economic value.
Second-quarter 2026 consolidated revenue reached $101.9 million, compared with $39.7 million a year earlier. DefenCath generated $66.1 million, while the acquired Melinta anti-infective portfolio contributed $35.8 million. Net income increased to approximately $26 million, or $0.29 per diluted share, while adjusted EBITDA climbed to $58.7 million from $22.4 million.
CorMedix Inc. (NASDAQ: CRMD) offers strong commercial growth, current profitability, and greater product diversification following the Melinta acquisition. Nevertheless, product concentration, reimbursement changes, acquisition integration, dialysis-provider purchasing patterns, and uncertainty surrounding normalized earnings remain important risks. Continued DefenCath adoption across major dialysis organizations could make CorMedix Inc. (NASDAQ: CRMD) one of the strongest small-cap biotechnology growth stories.
